The study of a possible correlation between serum levels of interleukin 17 and clinical severity in patients with allergic rhinitis
Allergic rhinitis (AR) is one of the most common allergic diseases, which affects ∼20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined.
To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition.
Patients and Methods:
During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing, and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed.
Revealed a significant elevation of serum IL-17 levels with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy.
These preliminary results added new data about the use of injective immunotherapy as well as reported on the use of sublingual immunotherapy.
Document Type: Research Article
Affiliations: 1: From the Microbiology and Immunology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt 2: ENT Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Publication date: 01 October 2017
- Allergy and Rhinology will no longer be hosted on Ingenta Connect as of July 10, 2018. For all subscription orders where the customer's end-user address is in the USA, Canada, Central and South America including the Caribbean, please contact [email protected] For all subscription orders where the customer's end user address is in the UK, Europe, Middle East, Africa and Australasia, please contact [email protected]